Terlipressin

In plain language

Terlipressin is a hospital drug used to raise blood pressure in a specific, life-threatening situation: kidney failure caused by advanced liver disease (hepatorenal syndrome type 1). It is sold as Terlivaz in the U.S.

It is a slow-release form of vasopressin, the body's own blood-pressure hormone: three small amino-acid tags are attached that are clipped off gradually, releasing the active drug over hours. Its U.S. label carries a boxed warning because it can cause breathing failure from fluid overload in this fragile population.

For students

Terlipressin is triglycyl-lysine-vasopressin (about 1,227 Da), a prodrug: a 12-residue construct whose three N-terminal glycines are enzymatically removed in vivo, freeing lysine-vasopressin slowly, extending effective half-life and allowing 4-6 hourly dosing. It is a V1a-selective vasopressin agonist (with some V2 activity), causing splanchnic and systemic vasoconstriction.

Used for hepatorenal syndrome type 1 (HRS-1) and variceal bleeding, its U.S. approval in 2022 rested on the CONFIRM trial (300 patients randomized 2:1 to terlipressin plus albumin or placebo plus albumin): verified HRS reversal in 29% versus 16% of placebo patients. The boxed warning for respiratory failure within 3 days (particularly in patients with low baseline oxygen or high creatinine) came from this same trial, illustrating the tight benefit-risk calculus in advanced cirrhosis.

For researchers and instructors

Biochemistry. Prodrug design via sequential N-terminal glycine cleavage by tissue peptidases is a textbook example of using metabolic activation to smooth pharmacokinetics.

Pharmacology. V1a-mediated splanchnic vasoconstriction improves renal perfusion pressure; concurrent albumin is mandatory; contraindications include hypoxia and ongoing coronary or mesenteric ischemia.

Human evidence. CONFIRM is the pivotal trial for the U.S. HRS-1 indication; European and Chinese randomized data for variceal bleeding support its use there; prior smaller HRS trials (OTC-TLi-HRS-01, REVERSE) were mixed, and terlipressin has been declined for pulmonary hypertension and other indications.

Teaching point. Teaches the complexity of boxed warnings that coexist with demonstrated efficacy, and the role of albumin co-therapy in peptide drug use.